Ocuphire Pharma 2024 Corporate Presentation

Ocuphire Pharma's July 2024 corporate presentation outlining its clinical development pipeline and commercial strategy. The company is focused on APX3330 for diabetic retinopathy treatment, the RYZUMVI commercial launch, and partnerships including a collaboration with Viatris. The presentation highlights the company's experienced ophthalmology team and capital position to advance its product candidates.